iECURE Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 38

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $65M

  • Investors
  • 6

iECURE General Information

Description

Developer of an in vivo genome editing platform designed to develop gene insertion therapies for severe inherited neurometabolic disorders. The company offers variant-agnostic targeted gene insertion technology and investigational gene therapies, enabling healthcare providers and patients with inherited genetic disorders to access potential therapeutic treatment options.

Contact Information

Website
www.iecure.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1777 Sentry Parkway
  • Building Number 14, Suite 200
  • Blue Bell, PA 19422
  • United States
+1 (267)
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 1777 Sentry Parkway
  • Building Number 14, Suite 200
  • Blue Bell, PA 19422
  • United States
+1 (267)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iECURE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 16-Jul-2025 $65M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 09-Sep-2021 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2020 Completed Startup
To view iECURE’s complete valuation and funding history, request access »

iECURE Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A1
Series A
To view iECURE’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

iECURE Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an in vivo genome editing platform designed to develop gene insertion therapies for severe inherited neurom
Other Pharmaceuticals and Biotechnology
Blue Bell, PA
38 As of 2025

New York, NY

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iECURE Competitors (34)

One of iECURE’s 34 competitors is Attune Pharmaceuticals, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Attune Pharmaceuticals Venture Capital-Backed New York, NY
Voyager Therapeutics Formerly VC-backed Lexington, MA
Sanescohealth Corporation Asheville, NC
Ardelyx Formerly VC-backed Waltham, MA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 34 competitors. Get the full list »

iECURE Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iECURE Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Double Point Ventures Venture Capital Minority
LYFE Capital PE/Buyout Minority
Novo Holdings Venture Capital Minority
OrbiMed Growth/Expansion Minority
Versant Ventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

iECURE FAQs

  • When was iECURE founded?

    iECURE was founded in 2020.

  • Where is iECURE headquartered?

    iECURE is headquartered in Blue Bell, PA.

  • What is the size of iECURE?

    iECURE has 38 total employees.

  • What industry is iECURE in?

    iECURE’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is iECURE a private or public company?

    iECURE is a Private company.

  • What is the current valuation of iECURE?

    The current valuation of iECURE is .

  • What is iECURE’s current revenue?

    The current revenue for iECURE is .

  • How much funding has iECURE raised over time?

    iECURE has raised $115M.

  • Who are iECURE’s investors?

    Double Point Ventures, LYFE Capital, Novo Holdings, OrbiMed, and Versant Ventures are 5 of 6 investors who have invested in iECURE.

  • Who are iECURE’s competitors?

    Attune Pharmaceuticals, Voyager Therapeutics, Sanescohealth, Ardelyx, and Neurona Therapeutics are some of the 34 competitors of iECURE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process